selected scholarly activity
-
conferences
- Automated Segmentation of Hard Exudates Using SD-OCT in Patients with Diabetic Macular Edema from the Phase 2b ALTIMETER Study. Investigative Ophthalmology and Visual Science. 2024
- Efficacy and Safety of Faricimab in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME. Investigative Ophthalmology and Visual Science. 2024
- Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema. Investigative Ophthalmology and Visual Science. 2024
- Key clinical and anatomic outcomes from the YOSEMITE/RHINE trials of faricimab in patients with DME. Investigative Ophthalmology and Visual Science. 2024
- Greater reduction in hyperreflective foci with faricimab compared to aflibercept in patients with diabetic macular oedema. Acta Ophthalmologica. 2024
- Improved anatomical control with faricimab in the phase 3 YOSEMITE/RHINE trials in diabetic macular oedema. Clinical and Experimental Ophthalmology. 934-935. 2023
- Automated Segmentation of Hyperreflective Foci in Diabetic Macular Edema shows Greater Volume Reduction by Faricimab vs Aflibercept in Phase 3 YOSEMITE and RHINE. Investigative Ophthalmology and Visual Science. 2023
- Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME. Investigative Ophthalmology and Visual Science. 2023
- Faricimab reduces macular leakage vs aflibercept in patients with DME. Investigative Ophthalmology and Visual Science. 2023
- Faster time to retinal fluid control with faricimab versus aflibercept in patients with DME in the phase 3 YOSEMITE/RHINE trials. Investigative Ophthalmology and Visual Science. 2023
- Institutional Readiness for COVID-19 Parturient and the Ethical Trilemma of healthcare staff safety versus maternal and fetal safety. Anesthesia and Analgesia. 609-612. 2021
- Grading OCT characteristics did not clearly predict treatment outcomes in the RELIGHT study participants. Investigative Ophthalmology and Visual Science. 2016
-
journal articles
- INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE).. Eye. 2024
- Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema. Investigative Ophthalmology and Visual Science. 65:26-26. 2024
- Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA. Ophthalmology and Therapy. 6:175-186. 2017
- Tetanus in developing countries: a case series and review. Canadian Journal of Anaesthesia. 56:307-315. 2009
- Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Canadian Journal of Cardiology. 24:S38-S40. 2008